WO2020219829A1 - Compositions comprising non-crystalline forms of cannabidiol - Google Patents

Compositions comprising non-crystalline forms of cannabidiol Download PDF

Info

Publication number
WO2020219829A1
WO2020219829A1 PCT/US2020/029745 US2020029745W WO2020219829A1 WO 2020219829 A1 WO2020219829 A1 WO 2020219829A1 US 2020029745 W US2020029745 W US 2020029745W WO 2020219829 A1 WO2020219829 A1 WO 2020219829A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cannabidiol
mass
percent
terpene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/029745
Other languages
French (fr)
Inventor
Nixon MALCOLM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Extraction Systems LLC
Original Assignee
Natural Extraction Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/408,428 external-priority patent/US10993928B2/en
Application filed by Natural Extraction Systems LLC filed Critical Natural Extraction Systems LLC
Priority to CA3137559A priority Critical patent/CA3137559A1/en
Publication of WO2020219829A1 publication Critical patent/WO2020219829A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis

Definitions

  • Cannabidiol exists as a crystalline solid at room temperature, which has a melting point of 151 degrees Fahrenheit (66 degrees Celsius). Crystalline cannabidiol lacks robust bioavailability, for example, because the human body is incapable of melting it.
  • the pharmaceutical EPIDIOLEX® contains cannabidiol dissolved in sesame seed oil to increase bioavailability.
  • Cannabidiol crystallization confounds vaporization in electronic cigarettes and vaporizers because
  • crystallization inhibits the flow of cannabidiol toward a heating element.
  • Prior art methods to inhibit the crystallization of cannabidiol for use in electronic cigarettes and vaporizers include the dissolution of cannabidiol in organic solvents such as propylene glycol and triglycerides. Organic solvents dilute the cannabidiol, however, and present unknown health risks. Improved cannabidiol formulations are therefore desirable.
  • compositions comprising liquid cannabidiol, which have either a freezing point or a glass-liquid transition temperature of less than the melting point of pure cannabidiol.
  • the freezing point or the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
  • This patent document discloses that the melting point of cannabidiol can be lowered— or eliminated— by dissolving small amounts of specific solutes in liquid cannabidiol.
  • the melting point of cannabidiol can be reduced to less than 70 degrees Fahrenheit (or less than 21 degrees Celsius), for example, to provide concentrated cannabidiol compositions that are liquids at room temperature. This discovery allows novel products including concentrated cannabidiol vape oil.
  • compositions comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, in which: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is humulene; the terpene oxidation product is either bicyclohumuladiol, tricyclohumuladiol, tricyclohumuladiol II, humulenol II, humulene epoxide I, humulene epoxide II, or humulene epoxide III; the composition comprises the humulene and the terpene oxidation product at a concentration of at least 70 percent and no greater
  • the terpene oxidation product is bicyclohumuladiol.
  • the terpene oxidation product is tricyclohumuladiol.
  • the terpene oxidation product is tricyclohumuladiol II.
  • the terpene oxidation product is humulenol II.
  • the terpene oxidation product is humulene epoxide I.
  • the terpene oxidation product is humulene epoxide II.
  • the terpene oxidation product is humulene epoxide III.
  • compositions comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is beta- caryophyllene; the terpene oxidation product is caryophyllene oxide; the composition comprises the beta-caryophyllene and the caryophyllene oxide at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees
  • compositions comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is alpha- bisabolol; the terpene oxidation product is either caryophyllene oxide or humulene epoxide II; the composition comprises the alpha-bisabolol and the terpene oxidation product at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (
  • compositions comprising (i) cannabidiol at a concentration of at least 50 percent and no greater than 99.5 percent by mass and (ii) one or more solutes selected from terpenes, terpene alcohols, and terpenoids at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass, in which: the one or more solutes are dissolved in the cannabidiol; the composition has either a freezing point or a glass-liquid transition temperature; and the freezing point or the glass-liquid transition temperature is either (i) at least 50 degrees Fahrenheit less than the freezing point of pure cannabidiol or (ii) at least 27 degrees Celsius less than the freezing point of pure cannabidiol.
  • the composition comprises the cannabidiol at a concentration of at least 65 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass.
  • the composition comprises the cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass.
  • the composition comprises the cannabidiol at a concentration of at least 75 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 25 percent by mass.
  • Formula XV does not depict stereochemistry, and“cannabichromene” encompasses both stereoisomers of Formula XV.
  • the composition has a freezing point; the composition lacks a glass- liquid transition temperature; and the freezing point is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
  • the composition has a glass-liquid transition temperature; the composition lacks a freezing point; and the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
  • the composition lacks crystals of cannabidiol.
  • the composition comprises cannabidiol at a concentration of at least 75 percent and no greater than 99 percent by mass.
  • the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass.
  • the composition comprises tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; and the composition comprises the cannabidiol and the tetrahydrocannabinol at a ratio of at least 3: 1 and no greater than 200: 1 by mass.
  • the composition comprises (6a,S , ,10ai?)-6,6,9-trimethyl-3-pentyl- 6a, 7, 8, 10a-tetrahydro-6H -benzo[c]chromen- l -ol at a concentration of at least 0.05 percent and no greater than 5 percent by mass, in which the (6aV, 10aR )-6,6,9-trimethyl-3-pentyl-6a,7,8, 10a- tetrahydro-6H -benzo[c]chromen- l -ol is dissolved in the cannabidiol.
  • the composition comprises molecules having a boiling point of less than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass.
  • the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5 percent by mass.
  • the composition lacks propylene glycol.
  • the composition lacks triglycerides.
  • the composition lacks phospholipids.
  • the composition lacks waxes.
  • the composition is a liquid.
  • the composition has a viscosity, and the viscosity is less than 100 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius. In some specific embodiments, the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
  • the one or more solutes comprise one or more of alpha-bisabolol, alpha- phellandrene, alpha-pinene, alpha-terpinene, alpha-terpineol, beta-caryophyllene, beta-pinene, borneol, cadinene, camphene, camphor, caryophyllene oxide, citral, citron ellol, delta-3 -carene, eucalyptol, eugenol, gamma-terpinene, geraniol, guaiol, humulene, isopulegol, limonene, linalool, myrcene, nerol, nerolidol, ocimene, para-cymene, phytol, pulegone, terpineol, terpinolene, and valencene at a combined concentration of at least 0.5 percent and no greater than
  • the one or more solutes comprise one or more of alpha- bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass.
  • the one or more solutes comprise alpha-bisabolol.
  • the one or more solutes comprise beta-caryophyllene.
  • the one or more solutes comprise caryophyllene oxide.
  • the one or more solutes comprise humulene.
  • the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration of greater than
  • the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition comprises tetrahydrocannabinol at a concentration of greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of at least 3 : 1 and no greater than 200: 1 by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by
  • the composition comprises cannabichromene at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the composition comprises cannabichromene at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabichromene at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass.
  • the combination of cannabichromene and one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products is more effective at reducing the freezing point of liquid cannabidiol than the one or more solutes alone.
  • the composition comprises cannabigerol at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the
  • composition comprises cannabigerol at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabigerol at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass.
  • a method to manufacture a cannabidiol product comprising (i) providing a starting composition comprising liquid cannabidiol; and (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document.
  • a container comprising (i) a heating element and (ii) a chamber that contains at least 2 milligrams and no greater than 2 grams of a composition described anywhere in this patent document, wherein the heating element is in thermal
  • the container is configured to be connected to a battery such that the battery and the heating element are in electrical communication that allows the transfer of electrical energy from the battery to the heating element; the heating element is operable to convert the electrical energy into sufficient heat energy; and the sufficient heat energy is sufficient to heat the composition to a temperature greater than the boiling point of the cannabidiol.
  • the container is connected to the battery such that the battery and the heating element are in electrical communication.
  • a method to manufacture a cannabidiol product comprising (i) providing a composition comprising cannabidiol and one or more solutes, wherein the cannabidiol is a liquid, and the one or more solutes are dissolved in the cannabidiol; (ii) providing a starting container comprising a heating element; and (iii) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
  • a method to manufacture a cannabidiol product comprising (i) providing a starting composition comprising liquid cannabidiol; (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document; (iii) providing a starting container comprising a heating element; and (iv) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
  • Cannabinoids were extracted from organic industrial hemp using the system described in PCT Patent Application Publication No. 2016/161420 A1 to produce crude industrial hemp extract comprising 65-70% cannabidiol; 5-10% terpenes, terpene alcohols, and terpenoids; 2-3% tetrahydrocannabinol; and other volatile molecules including waxes and phospholipids.
  • the crude industrial hemp extract formed crystals of cannabidiol when stored at room temperature for 24 hours.
  • the cannabinoids of the crude industrial hemp extract were separated from other molecules by distillation in a VTA Short Path Distillation Plant VKL 70 (Verfahrenstechnische Anlagen GmbH & Co. KG, Germany) to produce a cannabinoid distillate comprising approximately 90% cannabidiol and 5% tetrahydrocannabinol. 10 grams of the cannabinoid distillate was combined with 0.1 grams of a terpene, terpene alcohol, and terpenoid blend obtained from True Terpenes (Oregon, USA) with heating to produce a liquid composition.
  • the blend contained beta- caryophyllene (41%), humulene (18%), linalool (13%), limonene, alpha-bisabolol, nerolidol, beta- pinene, citronellol, fenchol, and other molecules at lower concentrations.
  • the liquid composition was stored at room temperature for 1 year with intermittent exposure to light and air, and the composition produced no detectable crystals. Cooling the liquid below room temperature vitrified the composition into a glass without any detectable crystal formation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Various aspects of this patent document relate to (i) compositions comprising cannabidiol, which have either a freezing point or a glass-liquid transition temperature of less than the melting point of pure cannabidiol, (ii) containers that contain such compositions, and (iii) methods to manufacture cannabidiol products.

Description

COMPOSITIONS COMPRISING NON-CRYSTALLINE FORMS OF CANNABIDIOL
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application claims priority to U.S. Provisional Patent Application No. 62/839,564, filed April 26, 2019; U.S. Provisional Patent Application No. 62/845,231, filed May 8, 2019; U.S. Patent Application No. 16/408,428, filed May 9, 2019; U.S. Provisional Patent Application No. 62/860,224, filed June 11, 2019; and U.S. Provisional Patent Application No. 62/942,442, filed December 2, 2019, each of which is incorporated by reference in its entirety.
BACKGROUND
Cannabidiol exists as a crystalline solid at room temperature, which has a melting point of 151 degrees Fahrenheit (66 degrees Celsius). Crystalline cannabidiol lacks robust bioavailability, for example, because the human body is incapable of melting it. The pharmaceutical EPIDIOLEX® contains cannabidiol dissolved in sesame seed oil to increase bioavailability.
Consumers also vaporize and inhale cannabidiol to increase bioavailability. Cannabidiol crystallization confounds vaporization in electronic cigarettes and vaporizers because
crystallization inhibits the flow of cannabidiol toward a heating element. Prior art methods to inhibit the crystallization of cannabidiol for use in electronic cigarettes and vaporizers include the dissolution of cannabidiol in organic solvents such as propylene glycol and triglycerides. Organic solvents dilute the cannabidiol, however, and present unknown health risks. Improved cannabidiol formulations are therefore desirable.
SUMMARY
Various aspects of this patent document relate to compositions comprising liquid cannabidiol, which have either a freezing point or a glass-liquid transition temperature of less than the melting point of pure cannabidiol. In preferred embodiments, the freezing point or the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
DETAILED DESCRIPTION
This patent document discloses that the melting point of cannabidiol can be lowered— or eliminated— by dissolving small amounts of specific solutes in liquid cannabidiol. The melting point of cannabidiol can be reduced to less than 70 degrees Fahrenheit (or less than 21 degrees Celsius), for example, to provide concentrated cannabidiol compositions that are liquids at room temperature. This discovery allows novel products including concentrated cannabidiol vape oil.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, in which: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is humulene; the terpene oxidation product is either bicyclohumuladiol, tricyclohumuladiol, tricyclohumuladiol II, humulenol II, humulene epoxide I, humulene epoxide II, or humulene epoxide III; the composition comprises the humulene and the terpene oxidation product at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
In some preferred embodiments, the terpene oxidation product is bicyclohumuladiol.
In some preferred embodiments, the terpene oxidation product is tricyclohumuladiol.
In some preferred embodiments, the terpene oxidation product is tricyclohumuladiol II.
In some preferred embodiments, the terpene oxidation product is humulenol II.
In some preferred embodiments, the terpene oxidation product is humulene epoxide I.
In some preferred embodiments, the terpene oxidation product is humulene epoxide II.
In some preferred embodiments, the terpene oxidation product is humulene epoxide III.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is beta- caryophyllene; the terpene oxidation product is caryophyllene oxide; the composition comprises the beta-caryophyllene and the caryophyllene oxide at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass- liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein: the one or more solutes comprise a terpene and a terpene oxidation product; the terpene is alpha- bisabolol; the terpene oxidation product is either caryophyllene oxide or humulene epoxide II; the composition comprises the alpha-bisabolol and the terpene oxidation product at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 50 percent and no greater than 99.5 percent by mass and (ii) one or more solutes selected from terpenes, terpene alcohols, and terpenoids at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass, in which: the one or more solutes are dissolved in the cannabidiol; the composition has either a freezing point or a glass-liquid transition temperature; and the freezing point or the glass-liquid transition temperature is either (i) at least 50 degrees Fahrenheit less than the freezing point of pure cannabidiol or (ii) at least 27 degrees Celsius less than the freezing point of pure cannabidiol. In some preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 65 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass. In some specific preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass.
In some very specific preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 75 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 25 percent by mass.
Figure imgf000005_0001
Figure imgf000006_0001
Formula IV. Beta-Caryophyllene *
Figure imgf000006_0002
Formula VI Humulene *
Figure imgf000007_0001
Formula VII. Bicyclohumuladiol *
Figure imgf000007_0002
Formula VIII. Tricyclohumuladiol *
Figure imgf000008_0001
Figure imgf000009_0001
Formula XV. Cannabichromene†
Figure imgf000010_0001
Figure imgf000011_0001
* Formulas IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV depict stereochemistry, but each Common Name as used both in this patent specification and in the patent claims encompasses both the depicted stereochemistry of a Chemical Formula and each stereoisomer of a Chemical Formula because a probability distribution of each stereoisomer exists in natural products and because accredited cannabinoid testing laboratories generally do not distinguish stereoisomers;
† Formula XV does not depict stereochemistry, and“cannabichromene” encompasses both stereoisomers of Formula XV. In some embodiments, the composition has a freezing point; the composition lacks a glass- liquid transition temperature; and the freezing point is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition has a glass-liquid transition temperature; the composition lacks a freezing point; and the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition lacks crystals of cannabidiol.
In some embodiments, the composition comprises cannabidiol at a concentration of at least 75 percent and no greater than 99 percent by mass.
In some embodiments, the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass.
In some embodiments, the composition comprises tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; and the composition comprises the cannabidiol and the tetrahydrocannabinol at a ratio of at least 3: 1 and no greater than 200: 1 by mass.
In some embodiments, the composition comprises (6a,S,,10ai?)-6,6,9-trimethyl-3-pentyl- 6a, 7, 8, 10a-tetrahydro-6H -benzo[c]chromen- l -ol at a concentration of at least 0.05 percent and no greater than 5 percent by mass, in which the (6aV, 10aR )-6,6,9-trimethyl-3-pentyl-6a,7,8, 10a- tetrahydro-6H -benzo[c]chromen- l -ol is dissolved in the cannabidiol.
In some embodiments, the composition comprises molecules having a boiling point of less than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass.
In some embodiments, the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5 percent by mass.
In some preferred embodiments, the composition lacks propylene glycol.
In some preferred embodiments, the composition lacks triglycerides.
In some preferred embodiments, the composition lacks phospholipids.
In some preferred embodiments, the composition lacks waxes.
In some embodiments, the composition is a liquid.
In some embodiments, the composition has a viscosity, and the viscosity is less than 100 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius. In some specific embodiments, the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the one or more solutes comprise one or more of alpha-bisabolol, alpha- phellandrene, alpha-pinene, alpha-terpinene, alpha-terpineol, beta-caryophyllene, beta-pinene, borneol, cadinene, camphene, camphor, caryophyllene oxide, citral, citron ellol, delta-3 -carene, eucalyptol, eugenol, gamma-terpinene, geraniol, guaiol, humulene, isopulegol, limonene, linalool, myrcene, nerol, nerolidol, ocimene, para-cymene, phytol, pulegone, terpineol, terpinolene, and valencene at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass. In some specific embodiments, the one or more solutes comprise one or more of alpha- bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass.
In some preferred embodiments, the one or more solutes comprise alpha-bisabolol.
In some preferred embodiments, the one or more solutes comprise beta-caryophyllene.
In some preferred embodiments, the one or more solutes comprise caryophyllene oxide.
In some preferred embodiments, the one or more solutes comprise humulene. In some very specific embodiments, the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration of greater than 5 percent by mass; the composition has a glass-liquid transition temperature; the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius; the composition lacks a freezing point; the composition is a liquid; the composition has a viscosity; and the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some very specific embodiments, the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition comprises tetrahydrocannabinol at a concentration of greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of at least 3 : 1 and no greater than 200: 1 by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5 percent by mass; the composition has a glass-liquid transition temperature; the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius; the composition lacks a freezing point; the composition is a liquid; the composition has a viscosity; and the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition comprises cannabichromene at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the composition comprises cannabichromene at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabichromene at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass. The combination of cannabichromene and one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products is more effective at reducing the freezing point of liquid cannabidiol than the one or more solutes alone.
In some embodiments, the composition comprises cannabigerol at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the
composition comprises cannabigerol at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabigerol at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a starting composition comprising liquid cannabidiol; and (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document.
Various aspects of this patent document relate to a container comprising (i) a heating element and (ii) a chamber that contains at least 2 milligrams and no greater than 2 grams of a composition described anywhere in this patent document, wherein the heating element is in thermal
communication with the composition. In some specific embodiments, the container is configured to be connected to a battery such that the battery and the heating element are in electrical communication that allows the transfer of electrical energy from the battery to the heating element; the heating element is operable to convert the electrical energy into sufficient heat energy; and the sufficient heat energy is sufficient to heat the composition to a temperature greater than the boiling point of the cannabidiol. In some very specific embodiments, the container is connected to the battery such that the battery and the heating element are in electrical communication.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a composition comprising cannabidiol and one or more solutes, wherein the cannabidiol is a liquid, and the one or more solutes are dissolved in the cannabidiol; (ii) providing a starting container comprising a heating element; and (iii) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a starting composition comprising liquid cannabidiol; (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document; (iii) providing a starting container comprising a heating element; and (iv) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
The following example provides a framework to implement certain aspects of the disclosure, and this example does not limit the scope of this patent document or any claim that matures from the disclosure of this patent document.
Example 1. Production of compositions comprising cannabidiol that do not crystallize
Cannabinoids were extracted from organic industrial hemp using the system described in PCT Patent Application Publication No. 2016/161420 A1 to produce crude industrial hemp extract comprising 65-70% cannabidiol; 5-10% terpenes, terpene alcohols, and terpenoids; 2-3% tetrahydrocannabinol; and other volatile molecules including waxes and phospholipids. The crude industrial hemp extract formed crystals of cannabidiol when stored at room temperature for 24 hours.
The cannabinoids of the crude industrial hemp extract were separated from other molecules by distillation in a VTA Short Path Distillation Plant VKL 70 (Verfahrenstechnische Anlagen GmbH & Co. KG, Germany) to produce a cannabinoid distillate comprising approximately 90% cannabidiol and 5% tetrahydrocannabinol. 10 grams of the cannabinoid distillate was combined with 0.1 grams of a terpene, terpene alcohol, and terpenoid blend obtained from True Terpenes (Oregon, USA) with heating to produce a liquid composition. The blend contained beta- caryophyllene (41%), humulene (18%), linalool (13%), limonene, alpha-bisabolol, nerolidol, beta- pinene, citronellol, fenchol, and other molecules at lower concentrations.
The liquid composition was stored at room temperature for 1 year with intermittent exposure to light and air, and the composition produced no detectable crystals. Cooling the liquid below room temperature vitrified the composition into a glass without any detectable crystal formation.
This example demonstrates that small amounts of terpenes, terpene alcohols, and terpenoids can provide robust stabilization of cannabidiol in a liquid state and inhibit crystal formation over commercially -relevant timeframes, even when subjected to chemical stress, provided that lipids that comprise fatty acids are removed from the liquid state.

Claims

What is claimed is:
1. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is humulene;
the terpene oxidation product is either bicyclohumuladiol, tricyclohumuladiol,
tricyclohumuladiol II, humulenol II, humulene epoxide I, humulene epoxide II, or humulene epoxide III;
the composition comprises the humulene and the terpene oxidation product at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or
the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
2. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is beta-caryophyllene;
the terpene oxidation product is caryophyllene oxide;
the composition comprises the beta-caryophyllene and the caryophyllene oxide at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
3. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is alpha-bisabolol;
the terpene oxidation product is either caryophyllene oxide or humulene epoxide II;
the composition comprises the alpha-bisabolol and the terpene oxidation product at a ratio of at least 1 : 10 and no greater than 10,000: 1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or
the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
4. A composition, comprising cannabidiol at a concentration of 50% to 99.5% by mass and one or more solutes selected from terpenes, terpene alcohols, and terpenoids at a combined concentration of 0.5% to 40% by mass, in which:
the one or more solutes are dissolved in the cannabidiol;
the composition has either a freezing point or a glass-liquid transition temperature; and the freezing point or the glass-liquid transition temperature is either at least 50 degrees Fahrenheit less than the freezing point of pure cannabidiol or at least 27 degrees Celsius less than the freezing point of pure cannabidiol.
5. The composition of any one of claims 1-4, in which:
the composition has a freezing point;
the composition lacks a glass-liquid transition temperature; and
the freezing point is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
6. The composition of any one of claims 1-4, in which:
the composition has a glass-liquid transition temperature;
the composition lacks a freezing point; and
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
7. The composition of any one of claims 1-6, in which the composition lacks crystals of cannabidiol.
8. The composition of any one of claims 1-7, in which the composition comprises cannabidiol at a concentration of 75% to 99% by mass.
9. The composition of any one of claims 1-8, in which the composition lacks tetrahydrocannabinol at a concentration greater than 0.3% by mass.
10. The composition of any one of claims 1-8, in which:
the composition comprises tetrahydrocannabinol at a concentration greater than 0.3% by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; and
the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of 3: 1 to 200: 1 by mass.
11. The composition of any one of claims 1-10, comprising (6aS',10a R)-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydro-6iH-benzo[c]chromen-l-ol at a concentration of 0.05% to 5% by mass, in which the (6aS,,10aR )-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H -benzo[c]chromen-l-ol is dissolved in the cannabidiol.
12. The composition of any one of claims 1-11, in which the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95% by mass.
13. The composition of any one of claims 1-12, in which the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass.
14. The composition of any one of claims 1-13, in which the composition is a liquid.
15. The composition of any one of claims 1-14, in which the composition has a viscosity, and the viscosity is less than 100 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
16. The composition of claim 15, in which the viscosity is 50 millipascal-seconds to 50 pascal- seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
17. The composition of any one of claims 1-16, in which the one or more solutes comprise one or more of alpha-bisabolol, alpha-phellandrene, alpha-pinene, alpha-terpinene, alpha-terpineol, beta- caryophyllene, beta-pinene, bomeol, cadinene, camphene, camphor, caryophyllene oxide, citral, citronellol, delta-3 -carene, eucalyptol, eugenol, gamma-terpinene, geraniol, guaiol, humulene, isopulegol, limonene, linalool, myrcene, nerol, nerolidol, ocimene, para-cymene, phytol, pulegone, terpineol, terpinolene, and valencene at a combined concentration of 0.5% to 40% by mass.
18. The composition of any one of claims 1-17, in which the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 40% by mass.
19. The composition of any one of claims 1-18, in which:
the composition comprises cannabidiol at a concentration of 65% to 99% by mass;
the composition lacks crystals of cannabidiol;
the composition lacks tetrahydrocannabinol at a concentration greater than 0.3% by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 35% by mass;
the composition comprises molecules having a boiling point lower than either 360 degrees
Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95% by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass;
the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius;
the composition lacks a freezing point;
the composition is a liquid; and
the composition has a viscosity, and the viscosity is 50 millipascal-seconds to 50 pascal- seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
20. The composition of any one of claims 1-19, in which:
the composition comprises cannabidiol at a concentration of 65% to 99% by mass;
the composition lacks crystals of cannabidiol;
the composition comprises tetrahydrocannabinol at a concentration greater than 0.3% by mass; the tetrahydrocannabinol is dissolved in the cannabidiol;
the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of 3: 1 to 200: 1 by mass;
the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 35% by mass;
the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95% by mass;
the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass;
the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius;
the composition lacks a freezing point;
the composition is a liquid; and
the composition has a viscosity, and the viscosity is 50 millipascal-seconds to 50 pascal- seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
21. The composition of any one of claims 1-20, comprising cannabichromene at a concentration of at least 0.1 percent and no greater than 10 percent by mass.
22. The composition of any one of claims 1-21, comprising cannabigerol at a concentration of at least 0.1 percent and no greater than 10 percent by mass.
23. A method to manufacture a cannabidiol product, comprising:
providing a starting composition comprising liquid cannabidiol; and
dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition according to any one of claims 1-22.
24. A container, comprising (i) a heating element and (ii) a chamber that contains at least 2 milligrams and no greater than 2 grams of a composition according to any one of claims 1-22, wherein the heating element is in thermal communication with the composition.
25. A method to manufacture a cannabidiol product, comprising:
providing a composition comprising cannabidiol and one or more solutes, wherein the cannabidiol is a liquid, and the one or more solutes are dissolved in the cannabidiol;
providing a starting container comprising a heating element; and
inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce the container of claim 24.
26. A method to manufacture a cannabidiol product, comprising:
providing a starting composition comprising liquid cannabidiol;
dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition;
providing a starting container comprising a heating element; and
inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce the container of claim 24.
PCT/US2020/029745 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol Ceased WO2020219829A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3137559A CA3137559A1 (en) 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962839564P 2019-04-26 2019-04-26
US62/839,564 2019-04-26
US201962845231P 2019-05-08 2019-05-08
US62/845,231 2019-05-08
US16/408,428 US10993928B2 (en) 2019-04-26 2019-05-09 Compositions comprising non-crystalline forms of cannabidiol
US16/408,428 2019-05-09
US201962860224P 2019-06-11 2019-06-11
US62/860,224 2019-06-11
US201962942442P 2019-12-02 2019-12-02
US62/942,442 2019-12-02

Publications (1)

Publication Number Publication Date
WO2020219829A1 true WO2020219829A1 (en) 2020-10-29

Family

ID=72941782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/029745 Ceased WO2020219829A1 (en) 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol

Country Status (2)

Country Link
CA (1) CA3137559A1 (en)
WO (1) WO2020219829A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085724B2 (en) * 2010-09-17 2015-07-21 Lubri3ol Oilfield Chemistry LLC Environmentally friendly base fluids and methods for making and using same
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
WO2017158539A1 (en) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
US20180362741A1 (en) * 2015-07-30 2018-12-20 Sumitomo Rubber Industries, Ltd. Rubber composition
US20190091198A1 (en) * 2016-03-28 2019-03-28 Lihi BAR-LEV SCHLEIDER Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085724B2 (en) * 2010-09-17 2015-07-21 Lubri3ol Oilfield Chemistry LLC Environmentally friendly base fluids and methods for making and using same
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
US20180362741A1 (en) * 2015-07-30 2018-12-20 Sumitomo Rubber Industries, Ltd. Rubber composition
WO2017158539A1 (en) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
US20190091198A1 (en) * 2016-03-28 2019-03-28 Lihi BAR-LEV SCHLEIDER Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Also Published As

Publication number Publication date
CA3137559A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US20250144068A1 (en) Compositions comprising non-crystalline forms of cannabidiol
US10864459B2 (en) Methods to produce cannabinoid products from decarboxylated cannabinoid extracts
US10822320B2 (en) Methods to purify cannabinoids
CN103589515A (en) Supercritical carbon dioxide extraction method of high-purity lavender essential oil
US9867859B2 (en) Method for increasing cannabinol content in a lipid-based extract of cannabis
CA2999032A1 (en) Cannabinoid compositions and methods of making
US20200102283A1 (en) Methods for Obtaining Purified Cannabis Extracts and THCA Crystals
CN110177543A (en) Water-soluble composition comprising purifying cannboid
CN112638851A (en) Process for the gas phase decarboxylation of cannabinoids
US20190262304A1 (en) Preparation of a solution of cannabinoids for personal vaping
US20200297025A1 (en) Method of manufacturing vape oil including a cannabinoid for use in a vape device
CN103347990B (en) Use of at least one by-product of the vegetable oil refining industry to obtain purified vegetable oil total unsaponifiables
CA3071677A1 (en) Medicinal cannabis
CA3217137A1 (en) Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2020219829A1 (en) Compositions comprising non-crystalline forms of cannabidiol
MONSEF et al. GC/MS analysis of Citrus aurantium L. hydrolate and its comparison with the commercial samples
CN110724602A (en) Preparation method of rose essential oil balm, rose essential oil and production method and application of rose essential oil
Tambe et al. FTIR & GC-MS analysis of Ylang Ylang oil, comparative study of its chemical composition and concern regarding diethyl phthalate
Kumar et al. Getting fragrance from plants
CN105054284B (en) Electronic cigarette atomizing liquid of salubrious elegant odor type and preparation method thereof
WO2020097721A1 (en) Preparation of extracts and compositions comprising extracts
WO2020123383A1 (en) Compositions with novel cannabinoid and terpene profiles
US11857590B2 (en) Systems and methods for producing hemp extracts and compositions
WO2024113046A1 (en) Vaporizable cannabinoid compositions
CA3254720A1 (en) Endogenous stabilization of cannabinoids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20795672

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3137559

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20795672

Country of ref document: EP

Kind code of ref document: A1